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Background: Evidence has accumulated which suggests that sex steroids influence colorectal cancer development
and progression. We therefore assessed the association of repeat polymorphisms in the estrogen receptor β gene
(ESR2) and the androgen receptor gene (AR) with colorectal cancer risk and prognosis.
Methods: The ESR2 CA and AR CAG repeat polymorphisms were genotyped in 1798 cases (746 female, 1052 male)
and 1810 controls (732 female, 1078 male), matched for sex, age and county of residence. Colorectal cancer risk
associations overall and specific for gender were evaluated using multivariate logistic regression models adjusted
for sex, county of residence and age. Associations with overall and disease-specific survival were evaluated using
Cox proportional hazard models adjusted for established prognostic factors (diagnosis of other cancer after
colorectal cancer diagnosis, detection by screening, treatment with adjuvant chemotherapy, tumour extent, nodal
status, distant metastasis, body mass index, age at diagnosis and year of diagnosis) and stratified for grade of
differentiation. Heterogeneity in gender specific associations was assessed by comparing models with and without
a multiplicative interaction term by means of a likelihood ratio test.
Results: The average number of ESR2 CA repeats was associated with a small 5% increase in colorectal cancer risk
(OR = 1.05, 95% CI 1.01-1.10) without significant heterogeneity according to gender or tumoural ESR2 expression.
We found no indication for an association between the AR CAG repeat polymorphisms and risk of colorectal cancer.
The ESR2 CA and AR CAG repeat polymorphisms were not associated with overall survival or disease specific
survival after colorectal cancer diagnosis.
Conclusions: Higher numbers of ESR2 CA repeats are potentially associated with a small increase in colorectal
cancer risk. Our study does not support an association between colorectal cancer prognosis and the investigated
repeat polymorphisms.
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Short tandem repeatBackground
Colorectal cancer is increasingly being recognized as a
hormone related disease due to accumulating evidence
that sex steroids influence colorectal carcinogenesis and
prognosis [1]. Incidence rates of colorectal cancer are
lower in women than in men and the use of menopausal* Correspondence: a.rudolph@dkfz.de
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unless otherwise stated.hormone therapy has consistently found to be associated
with a reduced colorectal cancer risk [2,3]. The effects of
sex hormones are potentially exerted through the re-
spective nuclear receptors. In normal colorectal tissue,
the estrogen receptor β (ESR2) is the predominantly
expressed estrogen receptor, and estrogen receptor α,
which plays a major role in breast cancer development
and therapy [4], is expressed at very low levels [1]. An-
other nuclear hormone receptor expressed in colorectal
tissue is the androgen receptor (AR) [5,6]. Both receptorsl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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leading to specific modifications in gene expression [7,8].
A CA repeat exists in intron 5 of ESR2, and it was found
to be associated with serum androgen, sex hormone-
binding globulin (SHBG) and estradiol levels [9,10]. Simi-
larly, associations between the CAG repeat in exon 1 of
the X-linked AR with serum testosterone and estradiol
levels in men were observed [11-13]. The number of
AR CAG repeats was shown to have functional impli-
cations on the resulting protein with higher numbers
leading to decreased transcriptional activity [14,15].
Both polymorphisms were found to be associated with
colon cancer risk in a previous study [16]. Women har-
bouring two long alleles (≥25 CA repeats) of the ESR2
CA repeat and men having two alleles with ≥23 CAG
repeats in AR were at increased risk for colon cancer
compared to individuals with shorter alleles of the re-
spective polymorphism. Recent studies on prognosis
observed that men with metastatic colorectal cancer
harbouring two long alleles of the ESR2 CA repeat had
poorer overall and progression-free survival than men
with short alleles [17] and women with metastatic
colon cancer harbouring two long alleles had a signifi-
cantly reduced risk of dying compared to women with
at least one short allele [18]. Furthermore, loss of ESR2
expression in colorectal tumours was associated with
an increased risk of mortality [19]. Therefore, genetic
variation in ESR2 and AR may affect the action of sex
steroids on colonic epithelium and consequently influ-
ence the colorectal cancer susceptibility and prognosis.
Whether the AR CAG repeat is associated with colorec-
tal cancer prognosis has not been investigated so far.
With the present study, we aimed to investigate the as-
sociation between the AR CAG and ESR2 CA repeat poly-
morphism and colorectal cancer risk and prognosis, also
stratified by the tumoural expression of ESR2. In order
to compare our results with those previously published,
the analyses were also conducted separately in men and
women.
Methods
Study sample, data collection and follow-up
The DACHS study is an ongoing population-based case-
control study conducted in southwest Germany, which
has previously been described in detail [20,21]. Briefly,
cases were recruited from patients who received in-
patient treatment in a hospital of the study region due
to a first diagnosis of colorectal cancer. To be eligible,
participants had to be at least 30 years old and capable
to complete the interview. Controls were randomly se-
lected from lists of population registries and matched
according to gender, 5-year age groups and county of
residence. Individuals with a history of colorectal can-
cer were excluded from the study. The present studycomprised 746 female and 1052 male incident colorec-
tal cancer patients as well as 732 female and 1078
male controls recruited between January 01, 2003 and
December 31, 2007. Ancestry of the participants was
homogenous with about 1% being of non-European
descent. Patients diagnosed with any other cancer ex-
cept squamous and basal cell skin cancer before their
first diagnosis of colorectal cancer (N =160), patients
who died within 30 days after diagnosis and whose
death may be related to surgery (N =7), and patients
without follow-up information (N =7) were excluded
from the survival analyses, which comprised 665 female
and 959 male cases. Written informed consent was ob-
tained from all study participants and the study was
approved by the ethics committees of the University of
Heidelberg and the State Medical Boards of Baden-
Wuerttemberg and Rhineland-Palatinate, Germany.
Patients and controls were interviewed in person by
trained interviewers using standardized questionnaires.
In the interview, information on sociodemographic
factors, previous health examinations, medication such
as the use of menopausal hormone therapy and non-
steroidal anti-inflammatory drugs (NSAIDs), family his-
tory of colorectal cancer, and life-style related factors was
collected. Additionally, pathology reports and discharge
letters were collected. Self-reported use of menopausal
hormone therapy was validated for women entering the
study before December 31, 2006 [22]. The study partici-
pants were asked to provide either a blood sample or a
mouthwash sample.
On average three years after diagnosis, a questionnaire
was sent to the treating physicians of the patients to col-
lect information on therapy, and newly diagnosed con-
comitant diseases. A second follow-up questionnaire was
mailed to the patients about five years after diagnosis.
Vital status and date of death were obtained from the
population registries and the cause of death was verified
by death certificates obtained from the health authorities
in the Rhein-Neckar-Odenwald region. New diagnoses and
cancer recurrences were verified through medical records
of the attending physicians. In total 665 female and 959
male cases were included in the survival analysis.
Genotyping
Genomic DNA was extracted from blood (98%) or mouth-
wash samples (2%) using Flexigene Kit 250 (Qiagen,
Valencia, CA, USA) and Qiagen Mini Kit (Qiagen,
Valencia, CA, USA), respectively. Genomic regions con-
taining the AR and ESR2 microsatellite markers were
amplified by polymerase chain reaction (PCR). We used
previously reported primers [9]. The PCR reaction mix-
ture consisted of 4 ng genomic DNA in a 5 μl reaction
volume containing 1.5 mM magnesium chloride, 1x
reaction buffer, 0.20 μM deoxynucleoside triphosphates
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gen, Darmstadt, Germany) and 0.5 μM of each primer.
About 2 μl of the 1/10 diluted PCR product was added to
0.5 μl size marker and denaturized for 3 minutes at
95°C. The detection was done using the ABI 3130XL
Genetic Analyzer (Applied Biosystems, Carlsbad, CA,
USA) and the fluorescently labelled DNA fragments were
analysed by size using the GeneMapper 4.0 software
(Applied Biosystems, Carlsbad, CA, USA). A random
sample of 6.6% was genotyped twice for quality control.
Definition of variables
The repeat numbers in AR and ESR2 were averaged for
each individual, assuming that each increase in number
is related to a constant proportional change in relative
risk. For better illustration of the associations with dif-
fering levels of repeat number, we categorized the con-
tinuous variable of average repeat number into quartiles,
according to the distribution in controls. The genotypes
were also dichotomized in order to report results com-
parable to previous studies, based on the median repeat
number in controls (<22 repeats/≥22 for AR CAG re-
peats and <24 repeats/≥24 for ESR2 CA repeats).
To evaluate the ESR2-status of colorectal tumours,
ESR2 expression was measured immunohistochemically
in tissue microarrays [19]. For this study, we classified
samples with less than 10% of the cell nuclei showing
strong positive staining or with less than 50% of the nu-
clei showing weak positive staining as ESR2 negative.
ESR2 positivity was defined as weak staining of more
than 50% of the cell nuclei or strong positive staining in
at least 10% of the cell nuclei.
For survival analysis, follow-up time was calculated as
the time between the date of diagnosis and the date of
event or censoring. Events of interest were death from
any cause (overall survival) and death due to colorectal
cancer (disease-specific survival).
Statistical analysis
All statistical analyses were performed using SAS 9.2
(SAS Institute, Cary, NC, USA). Statistical significance was
determined according to the conventional significance-
level of α =5%.
Genotype frequencies were assessed in cases and con-
trols separately and tested for deviation from Hardy-
Weinberg equilibrium (HWE) in controls using a one
degree of freedom Chi-square test. Unconditional logis-
tic regression was used to calculate odds ratios (ORs) as
well as confidence intervals (CIs) for colorectal cancer
risk associated with genotypes. To test whether gender
specific associations are statistically different, we built a
multiplicative interaction term between the respective
genotype variable and gender and performed a log likeli-
hood ratio test. The models were adjusted for age andcounty of residence. The inclusion of additional colorec-
tal cancer risk factors did not change the OR estimates
substantially (changes <10% in all cases). The following
factors were assessed: having a first degree relative diag-
nosed with colorectal cancer, ever regular use of NSAIDs
(2+ times/week, ≥1 year), pack-years of smoking (in cat-
egories of 10 pack-years), average lifetime alcohol con-
sumption (g/day in quartiles), average physical activity in
the 12 months before diagnosis (in metabolic equivalent
of task (MET) hours/week quartiles), ever colorectal en-
doscopy, ever diagnosis of diabetes, consumption of red
meat in last 12 months (low, moderate, high) and body
mass index (BMI) ≥5 years before diagnosis/date of inter-
view (in five categories, <23 kg/m2, ≥23 to <25 kg/m2, ≥25
to <27 kg/m2, ≥27 to <30 kg/m2, ≥30 kg/m2). In second-
ary analysis, we evaluated risk associations according to
ESR2-status using multinomial logistic regression. Het-
erogeneity between the risk estimates was assessed using
unadjusted logistic regression models in case-case analyses.
Median follow-up time of cases after diagnosis was
computed using the reverse Kaplan-Meier method [23].
Regression analyses based on the Cox proportional haz-
ards models were applied to evaluate associations of the
polymorphisms with overall and disease-specific survival.
The models were determined using backward selection,
retaining variables with a p-value of ≤0.2. Validity of the
proportional hazards assumption was assessed by includ-
ing a time-dependent component for each explanatory
variable. The models were adjusted for tumour extent
(T1, T2, T3, T4), nodal status (N0, N1, N2), distant me-
tastasis (M0, M1), screening detection of colorectal can-
cer (yes/no), treatment with adjuvant chemotherapy
(yes/no), BMI at diagnosis (kg/m2, continuous), diagno-
sis of diabetes after colorectal cancer diagnosis (yes/no),
diagnosis of other cancer after colorectal cancer diagno-
sis (yes/no), age at diagnosis and year of diagnosis. The
models were additionally stratified for grade of diffe-
rentiation (well/moderate, poor/undifferentiated) as this
variable showed a time-dependent effect on overall sur-
vival. We accounted for left truncation of the follow-up
period. The association of the ESR2 and AR repeat poly-
morphisms with survival according to tumoural ESR2-
status was assessed using subgroup analysis. Heterogeneity
of ESR2-specific hazard ratios was evaluated using an
interaction term between ESR2-status and genotype.
Results
The distribution of relevant epidemiologic characteristics
for women and men are shown in Additional file 1:
Table S1. The median follow-up time was 48.4 months
in men and 49.9 months in women. For the AR CAG re-
peat, the genotype was successfully determined in 89.4%
of cases and 87.7% of controls. The genotyping error
rate calculated from the duplicated samples was 4.1%.
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type among men indicates a genotyping error. The re-
spective samples (20 cases, 16 controls) were excluded
from further analyses. For the ESR2 CA repeat, genotyp-
ing was successful in 87.9% of cases and 89.4% of controls.
The genotyping error rate was 0.8%. The distribution of
genotypes among controls did not significantly deviate
from HWE for any of the investigated variants, although
this could not be assessed for the AR CAG repeat among
male controls (HWE p-value was 0.14 for the AR CAG re-
peat and 0.98 for the ESR2 CA repeat). The allele frequen-
cies of the AR CAG and the ESR2 CA repeats are shown
in Figure 1.
The estimated ORs and 95% CIs for colorectal cancer
risk associated with the average number of the AR CAG
repeats and ESR2 CA repeats are displayed in Table 1.
The number of CAG repeats in AR was not associated
with colorectal cancer risk. A significant positive asso-
ciation with colorectal cancer risk was found with ave-
rage number of the CA repeats in ESR2 (OR per unitFigure 1 Frequencies of the average number of (A) CAG repeats in ARincrease in average repeat number =1.05, 95% CI 1.01 -
1.10, p =0.02). The association was significant in men
(OR =1.07, 95% CI 1.02 - 1.13, p =0.01) and not appar-
ent in women (OR =1.01, 95% CI 0.95 - 1.08, p =0.69),
although the p-value for heterogeneity by gender did
not indicate a significantly heterogeneous association
between men and women (p heterogeneity =0.24). As-
sociations of the repeat polymorphisms with colorectal
cancer risk did not differ for ESR2 positive and ESR2
negative cancer (Additional file 1: Table S2).
The AR CAG and ESR2 CA repeat polymorphisms
were not associated with overall or disease-specific sur-
vival for all stages of colorectal cancer in multivariate
analyses and the associations were not significantly dif-
ferent in men and women. The respective hazard ratios
(HRs) and CIs are presented in Table 2. No significant
associations between prognosis and the investigated
polymorphisms were observed when assessing hazard ra-
tios according to ESR2-status of the tumour (Additional
file 1: Table S3).and (B) CA repeats in ESR2.
Table 1 Number of AR CAG repeats and ESR2 CA repeats and associated colorectal cancer risk in the female and male study population
Overall Women Men
Genotype Cases N Controls N OR (95% CI)b Cases N Controls N OR (95% CI)c Cases N Controls N OR (95% CI)c p heterogeneity
AR CAG(n)
<20 average repeats 263 254 1.00 (Ref.) 88 94 1.00 (Ref.) 175 160 1.00 (Ref.)
≥20 to <22 average repeats 531 506 1.01 (0.82 - 1.25) 229 228 1.06 (0.75 - 1.51) 302 278 1.00 (0.76 - 1.31)
≥22 to <23.5 average repeats 370 400 0.89 (0.71 - 1.11) 182 189 1.03 (0.72 - 1.48) 188 211 0.82 (0.61 - 1.10)
≥23.5 average repeats 424 412 0.99 (0.79 - 1.23) 169 140 1.24 (0.85 - 1.80) 255 272 0.86 (0.65 - 1.13) 0.19d
average repeatsa 1588 1572 0.99 (0.96 - 1.01) 668 651 1.01 (0.96 - 1.06) 920 921 0.98 (0.95 - 1.01) 0.23e
p trend =0.34 p trend =0.68 p trend =0.15
<22/<22 repeats 645 610 1.00 (Ref.) 168 172 1.00 (Ref.) 477 438 1.00 (Ref.)
<22/≥22 repeats 324 324 0.91 (0.72 - 1.15) 324 324 1.03 (0.79 - 1.35) n/a n/a (no heterozygous)
≥22/≥22 repeats 619 638 0.91 (0.78 - 1.07) 176 155 1.14 (0.84 - 1.55) 443 483 0.84 (0.70 - 1.01) 0.09e
p trend =0.24 p trend =0.40 p trend =0.07
ESR2 CA(n)
<22 average repeats 348 409 1.00 (Ref.) 149 153 1.00 (Ref.) 199 256 1.00 (Ref.)
≥22 to <23.5average repeats 389 381 1.20 (0.98 - 1.47) 154 154 1.07 (0.77 - 1.49) 235 227 1.25 (0.96 - 1.64)
≥23.5 to <24 average repeats 226 227 1.17 (0.93 - 1.48) 98 90 1.14 (0.77 - 1.68) 128 137 1.20 (0.87 - 1.65)
≥24 average repeats 618 602 1.20 (1.00 - 1.45) 261 255 1.06 (0.78 - 1.46) 357 347 1.31 (1.02 - 1.70) 0.51d
average repeatsa 1581 1619 1.05 (1.01 - 1.10) 662 652 1.01 (0.95 - 1.08) 919 967 1.07 (1.02 - 1.13) 0.24e
p trend =0.02 p trend =0.69 p trend =0.01
<24/<24 repeats 323 347 1.00 (Ref.) 119 125 1.00 (Ref.) 204 222 1.00 (Ref.)
<24/≥24 repeats 755 814 0.99 (0.83 - 1.19) 335 334 1.03 (0.77 - 1.39) 420 480 0.95 (0.75 - 1.20)
≥24/≥24 repeats 503 458 1.17 (0.96 - 1.43) 208 193 1.10 (0.80 - 1.52) 295 265 1.21 (0.94 - 1.55) 0.71e
p trend =0.08 p trend =0.54 p trend =0.11
aAs continuous variable, bModels adjusted for sex, county of residence and age, cModels adjusted for county of residence and age, dP value for heterogeneity by gender with genotype in categories (3 df), eP value for

















Table 2 Associations between number of AR CAG repeats and ESR2 CA repeats and overall as well as disease-specific survival
Overall Women Men p heterogeneityc
Genotype OS HR (95% CI)b DSS HR (95% CI)b OS HR (95% CI)b DSS HR (95% CI)b OS HR (95% CI)b DSS HR (95% CI)b OS DSS
AR CAG(n)
<20 average repeats 1.00 (Ref.) 1.00 (Ref.) 1.00 (Ref.) 1.00 (Ref.) 1.00 (Ref.) 1.00 (Ref.)
≥20 to <22 average repeats 1.09 (0.78 - 1.53) 1.14 (0.77 - 1.69) 0.90 (0.50 - 1.62) 1.21 (0.59 - 2.47) 1.28 (0.84 - 1.97) 1.20 (0.73 - 2.00)
≥22 to <23.5 average repeats 1.11 (0.76 - 1.61) 1.26 (0.82 - 1.95) 0.90 (0.49 - 1.64) 1.17 (0.56 - 2.46) 1.12 (0.67 - 1.88) 1.34 (0.74 - 2.42)
≥23.5 average repeats 1.03 (0.72 - 1.46) 1.04 (0.69 - 1.58) 0.75 (0.41 - 1.37) 0.93 (0.44 - 1.96) 1.22 (0.78 - 1.91) 1.24 (0.72 - 2.12) 0.83c 0.99c
average repeatsa 1.00 (0.96 - 1.05) 1.01 (0.95 - 1.06) 0.96 (0.88 - 1.04) 0.98 (0.89 - 1.08) 1.02 (0.96 - 1.07) 1.03 (0.96 - 1.10) 0.45d 0.93d
p trend =0.97 p trend =0.84 p trend =0.31 p trend =0.67 p trend =0.56 p trend =0.46
<22/<22 repeats 1.00 (Ref.) 1.00 (Ref.) 1.00 (Ref.) 1.00 (Ref.) 1.00 (Ref.) 1.00 (Ref.)
<22/≥22 repeats 0.95 (0.70 - 1.28) 0.95 (0.66 - 1.36) 0.96 (0.62 - 1.49) 0.97 (0.59 - 1.60) (no heterozygous) (no heterozygous)
≥22/≥22 repeats 1.03 (0.80 - 1.33) 1.12 (0.84 - 1.51) 0.94 (0.58 - 1.53) 1.09 (0.63 - 1.89) 1.01 (0.74 - 1.37) 1.14 (0.78 - 1.65) 0.91d 0.60d
p trend =0.80 p trend =0.45 p trend =0.82 p trend =0.73 p trend =0.95 p trend =0.50
ESR2 CA(n)
<22 average repeats 1.00 (Ref.) 1.00 (Ref.) 1.00 (Ref.) 1.00 (Ref.) 1.00 (Ref.) 1.00 (Ref.)
≥22 to <23.5average repeats 0.82 (0.59 - 1.15) 0.92 (0.61 - 1.39) 0.66 (0.38 - 1.15) 0.79 (0.42 - 1.47) 0.76 (0.51 - 1.14) 1.11 (0.63 - 1.97)
≥23.5 to <24 average repeats 0.93 (0.64 - 1.35) 1.12 (0.73 - 1.73) 1.15 (0.67 - 1.98) 1.16 (0.61 - 2.20) 0.91 (0.54 - 1.53) 1.30 (0.69 - 2.44)
≥24 average repeats 0.76 (0.56 - 1.02) 0.91 (0.64 - 1.29) 0.73 (0.47 - 1.15) 0.80 (0.50 - 1.38) 0.83 (0.50 - 1.38) 1.00 (0.60 - 1.65) 0.56c 0.96c
average repeatsa 0.95 (0.89 - 1.02) 0.99 (0.91 - 1.07) 0.95 (0.86 - 1.06) 0.96 (0.86 - 1.08) 0.95 (0.86 - 1.03) 1.00 (0.89 - 1.12) 0.85d 0.81d
p trend =0.14 p trend =0.72 p trend =0.35 p trend =0.54 p trend =0.22 p trend =0.99
<24/<24 repeats 1.00 (Ref.) 1.00 (Ref.) 1.00 (Ref.) 1.00 (Ref.) 1.00 (Ref.) 1.00 (Ref.)
<24/≥24 repeats 0.79 (0.59 - 1.07) 0.88 (0.62 - 1.26) 0.74 (0.46 - 1.20) 0.89 (0.51 - 1.55) 0.88 (0.60 - 1.29) 0.99 (0.62- 1.58)
≥24/≥24 repeats 0.73 (0.53 - 1.00) 0.82 (0.57 - 1.19) 0.67 (0.40 - 1.12) 0.78 (0.43 - 1.40) 0.76 (0.51 - 1.15) 0.89 (0.54 - 1.46) 0.81d 0.84d
p trend =0.06 p trend =0.31 p trend =0.15 p trend =0.39 p trend =0.19 p trend =0.62
aAs continuous variable, bStratified for grade of differentiation (well/moderate, poor/undifferentiated) and adjusted for diagnosis of other cancer after colorectal cancer diagnosis (yes/no), colorectal cancer detected by
screening (yes/no), treatment with adjuvant chemotherapy (yes/no), tumour extent (T1, T2, T3, T4), nodal status (N0, N1, N2), distant metastasis (M0, M1), BMI (kg/m2, continuous), age at diagnosis and year of
diagnosis, cP-value for heterogeneity by gender with genotype in categories (3df), dP-value for heterogeneity by gender with genotype as continuous variable (1df), OS: overall survival, DSS: disease-specific survival,
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In the present population-based case-control study, the
average number of CA repeats in ESR2 was positively as-
sociated with colorectal cancer risk. We did not observe
significant associations between the number of CAG re-
peats in AR and colorectal cancer risk. Regarding colo-
rectal cancer prognosis, the CA repeat polymorphism in
ESR2 and the CAG repeat polymorphism in AR were
not associated with overall or disease-specific survival.
The ESR2 repeat polymorphism (having two alleles
of ≥25 CA repeats versus 24 CA repeats) was previously
reported to be associated with increased risk of colon
cancer among women, but not among men (OR women =
2.1 95% CI 1.2 - 3.6, OR men =1.0, 95% CI 0.6 - 1.6, p
heterogeneity =0.03) [16]. We found a similar associ-
ation of increasing repeat number with increased risk of
colorectal cancer, although significantly so in the overall
study population and without significantly different as-
sociations according to gender. In contrast to the asso-
ciations observed here and by Slattery et al., a Japanese
study reported a more than six-fold increased risk of
colorectal cancer for women harbouring two ESR2 short
alleles (<22 repeats) compared to women harbouring
two long alleles (≥22 repeats) [24]. Yet in another in-
dependent study, having two ESR2 alleles with ≥22 CA
repeats compared to having two shorter ESR2 alleles
with <22 CA repeats was associated with an increased
risk of colon cancer among Japanese women [25]. The
discrepancy of the obtained results may be due to chance
in light of the relatively small number of cases investigated
in both Japanese studies (61 female colorectal cases and
151 female colon cases, respectively) and differences in
allele frequencies by ethnicity.
Two studies reported gender-specific associations of
the ESR2 CA repeat polymorphism with overall survival
among patients with metastatic colorectal and colon
cancer. In the study by Gordon et al., men with two long
alleles (≥22 repeats) had poorer overall and progression-
free survival than men with at least one short allele (<22
repeats) [17]. Press et al. reported the same association
for men, but found further evidence for an opposite as-
sociation among women [18]. In metastatic colorectal
cancer patients of the present study, there was no asso-
ciation between the ESR2 CA repeat polymorphism and
overall survival overall or by gender (data not shown). In
addition, an association between tagging SNPs in the
promoter region of ESR2 and an improved overall survival
after a diagnosis of colorectal cancer has been reported
by Passarelli et al. based on five prospective case-cohorts
[26]. Compared to our study, the patient sample analysed
by Passarelli et al. had similar 5-year overall survival and
distribution of tumour characteristics, but longer median
follow-up after diagnosis (5.0 to 9.1 years). Taking into
account the reported associations and given that theexpression of ESR2 in tumour tissue of colorectal can-
cer patients has been associated with overall survival
[19,27], it cannot be ruled out that genetic variation
influencing ESR2 expression plays a role in colorectal
cancer prognosis.
Estrogens are known to regulate the proliferation and
differentiation of breast, endometrial and various other
tissues [28]. Experimental studies indicate that this is
also true for the colonic epithelium [1,29-31]. Estrogen
signalling in the colon is most likely mediated by ESR2,
which is highly expressed in both colon epithelial cell
lines and human colon epithelium tissue samples [1,32].
A lack of ESR2 expression in human colon adenocarcin-
oma has been reported, suggesting that ESR2 might be a
tumour suppressor [19,33-35]. However, our results do
not support a differential association of the ESR2 CA
repeat with colorectal cancer risk or prognosis accor-
ding to ESR2 status. A functional study by Ugai et al.
indicated that the number of CA repeats in ESR2 has
no effect on ESR2 transcription [36]. The CA repeat
polymorphism in ESR2 may therefore predominantly
affect other processes such as splicing and translation
of ESR2 RNA or ESR2 signalling.
Regarding the relationship between colorectal cancer
risk and the AR CAG repeat polymorphism, Slattery
et al. [16] reported an increased risk for colon cancer for
men having two alleles with 23 CAG repeats or more.
Their finding is not supported by the present investiga-
tion in which the number of CAG repeats in AR was not
associated with colorectal cancer risk in men or in
women. This study investigated for the first time the as-
sociation between the AR CAG repeat polymorphism and
colorectal cancer prognosis and did not find a significant
association with overall or disease-specific survival. How-
ever, the genotyping error rate calculated from the du-
plicated samples was relatively high for the AR CAG
repeat polymorphism (4.1%). The misclassification due
to genotyping error may have affected study power when
investigating associations with the AR CAG repeat poly-
morphism [37].
Conclusions
In summary, alleles with higher numbers of ESR2 CA re-
peats are potentially associated with a small increase in
colorectal cancer risk. Further large epidemiological stud-
ies as well as functional studies are needed to elucidate
the role of ESR2 and AR polymorphisms in colorectal can-
cer development and prognosis.
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Additional file 1: Table S1. Distribution of selected risk and preventive
factors for colorectal cancer in the female and male study population.
Table S2. Number of CAG repeats in AR and CA repeats in ESR2 and
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